Aptinyx Reports Third Quarter 2019 Financial Results and Highlights
12 nov. 2019 16h01 HE
|
Aptinyx Inc.
Initiated two Phase 2 studies of NYX-2925 in chronic pain conditions On track to have four Phase 2 studies ongoing by year end across pipeline of CNS product candidates Conference call today at 5:00...
Aptinyx Initiates Two Phase 2 Studies of NYX-2925 in Patients with Chronic Centralized Pain Conditions
12 nov. 2019 07h27 HE
|
Aptinyx Inc.
200-patient painful diabetic peripheral neuropathy study and 300-patient fibromyalgia study build on previous compelling data obtained in these indications Top-line efficacy and safety data...
Aptinyx to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019
05 nov. 2019 08h07 HE
|
Aptinyx Inc.
EVANSTON, Ill., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
Aptinyx Announces Results of Phase 2 Fibromyalgia Study of NYX-2925 Have Been Selected for Late-Breaking Presentation at the American College of Rheumatology Annual Meeting
28 oct. 2019 07h57 HE
|
Aptinyx Inc.
Study met primary and secondary endpoints – statistically significant effects on neuroimaging biomarkers and patient-reported measures ePoster to be presented at ACR Annual Meeting on Tuesday,...
Aptinyx to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference
30 sept. 2019 07h03 HE
|
Aptinyx Inc.
EVANSTON, Ill., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
Three Recent Preclinical Publications Highlight NMDA Receptor Activation Facilitated by Aptinyx’s NYX-2925
26 sept. 2019 08h07 HE
|
Aptinyx Inc.
EVANSTON, Ill., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
Aptinyx Reports Second Quarter 2019 Financial Results and Highlights
12 août 2019 06h33 HE
|
Aptinyx Inc.
Reported that NYX-2925 met primary and secondary endpoints in Phase 2 fibromyalgia study On track to initiate three additional Phase 2 studies in 2H 2019 across pipeline of CNS product candidates ...
Aptinyx Reports Positive Top-line Data from Phase 2 Study of NYX-2925 in Patients with Fibromyalgia, Demonstrating Significant Effects on Both Biomarkers and Patient-Reported Pain
10 juin 2019 07h23 HE
|
Aptinyx Inc.
NYX-2925 demonstrated statistically significant effects on a range of neuroimaging biomarkers and patient-reported outcomes, including pain scores Neuroimaging biomarkers correlated with...
Cannabidiol (CBD) Market To Reach USD 16.32 Billion By 2026 | Reports And Data
06 mai 2019 11h52 HE
|
Reports And Data
The growth of the market is driven by the increased R&D investment in the healthcare industry and rising acceptance of cannabis globally. Market Size – USD 1.04 Billion in 2018, Market Growth -...
New Alliances Push Inspire's Growth to 100 Partners, 750,000 Patients and Caregivers
11 mai 2016 07h00 HE
|
Inspire
ARLINGTON, VA--(Marketwired - May 11, 2016) - Inspire, the leading social network for health, has added new nonprofit patient advocacy organizations -- including one focused on cancer...